Page 55 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 55
<200 mg/dL NR
(min) (hours) Uptake Fasting inter val period 60 +- 10 ≥6 50 ≥6
<180 mg/dL
<=8 mmol/L
NR
90 6
370 370
<200 mg/dL NR
<175 mg/dL
15·8 mmol/L range: 3·4-
Glucose
Predictive value of interim PET in DLBCL
before tracer Measured injection NR
90-160 mg/dL <180 mg/dL
NR
mean 90 ≥6 NR NR NR NR SD 22
<=11 mmol/L
median fasting 69, mean 70 +- 16 60 ≥6
60 ≥6
5·18/ 3·7/kg kg 5/kg
40-60 ≥6
5·5/kg
PET/CT
60 ≥4
60-90 6
4·4-7·4/kg
60 4-6 60-90 ≥6 97·5 +- ≥6 32·8
200-365 296-444 3·7/kg
dose (MBq) F-FDG 18 Scan Procedures PET only PET/CT or
Interpretation Criteria for positive scan
Aver- age 630 NR NR
393+-124 5.4/kg
PET/CT
3 NM
Deauville 4-5
5/kg
PET/CT
2 NM
IHP
PET/CT PET/CT
2 NM 3 NM
4-5 4-5
Deauville Deauville
Both
1 NM + 1 RAD
PET/CT
Both
PET/CT
3 reviewers
IHP
NR
2 (and 4)
PET/CT Both
NR
Both
PET/CT Both
Interpreters
1 NM ≥2 NM NR
2 out of 5 (random), 2 NM from own specializing in NM 2 physicians discrep: 3rd 4 NM
dept
2 NM
NR
4-5
Deauville
4-5
Deauville
NR
2
4-5
Deauville
NR
2
Deauville a 4-5
(11-14)
c Deauville 4-5 Deauville Custom Days from diagnosis
18 (IQR 17-21)
63 (21-126)
Min 10 days
1, 2 or 3
2, 3 or 4
1
42
43
41 b Mylam et al (2014)
Carr et al (2014)
Dabaja et al (2014)
Deauville 4-5
NR
3 or 4
44
Nols et al (2014)
Deauville 4-5
IHP
cycle
rd
2 days before 3
18 (16-21)
Table 2 Interim F-FDG PET characteristics 18
Days after previous treatment median 19·7 +- 2·3 (range) NR 20
2
R-CHOP 21: 19+-4
R-CHOP14/R-
ACVBP: 13+-2
16 (3-27)
PET timing Interim F-FDG Timing 2 or 3 18 2
34
35
Fan et al (2017)
Kim et al (2017)
2 (if positive
also after 4
2 or 3
2
3 or 4
2
First author, year
39
37
40
De Oliveira Costa et
Mamot et al (2015)
36
Kong et al (2016)
Zhang et al (2015)
Mikhaeel et al
38
al (2016)
(2016)
45
47
Fuertes et al (2013)
Gonzalez-Barca et al
46
Itti et al (2013)
(2013)
48
Lanic et al (2012)
53
3
